Alessandro Parisi, Blandine Delaunay, Giada Pinterpe, Antoine Hollebecque, Jean Frederic Blanc, Mohamed Bouattour, Eric Assenat, Meher Ben Abdelghani, Matthieu Sarabi, Monica Niger, Caterina Vivaldi, Mario Mandalà, Andrea Palloni, Maria Bensi, Silvio Ken Garattini, David Tougeron, Pierre Combe, Massimiliano Salati, Margherita Rimini, Chiara Alessandra Cella, Marco Tucci, Anna Diana, Elena Mori, Raffaella Longarini, Pascal Artru, Gael Roth, Ludovic Evesque, Agathe Vienne, Anthony Turpin, Sandrine Hiret, Vincent Bourgeois, Camille Herve, Rodolphe Paulon, Marion Stacoffe, David Malka, Cindy Neuzillet, Julien Edeline, Astrid Lievre, Rosine Guimbaud, Marie Christelle Pajiep Chapda, Lorenza Rimassa, Riccardo Giampieri, Juan Valle, Rossana Berardi, Nadim Fares
BACKGROUND: Pemigatinib is approved for patients with pretreated, locally advanced or metastatic CCA harboring FGFR2 rearrangements or fusions. We aim to assess the effectiveness and safety of pemigatinib in real-world setting. MATERIAL AND METHODS: A joint analysis of two multicentre observational retrospective cohort studies independently conducted in France and Italy was performed. All consecutive FGFR2-positive patients affected by CCA and treated with pemigatinib as second- or further line of systemic treatment in clinical practice, within or outside the European Expanded Access Program, were included...
March 2024: European Journal of Cancer